<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04067336</url>
  </required_header>
  <id_info>
    <org_study_id>KO-MEN-001</org_study_id>
    <nct_id>NCT04067336</nct_id>
  </id_info>
  <brief_title>First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>A Phase 1/2A First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients With Relapsed or Refractory Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kura Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kura Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess&#xD;
      KO-539, a menin-MLL(KMT2A) inhibitor, in patients with refractory or relapsed acute myeloid&#xD;
      leukemia (AML).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Phase 1/2a, first-in-human (FIH), open-label, dose-escalation and&#xD;
      dose-validation/expansion study will assess KO-539, a menin-MLL(KMT2A) inhibitor, in patients&#xD;
      with refractory or relapsed acute myeloid leukemia (AML). The dose-escalation part of the&#xD;
      study (part 1a) will determine the maximal tolerated dose (MTD). The&#xD;
      dose-validation/expansion part of the study (part 1b) will determine the safety,&#xD;
      tolerability, and minimal biologically effective dose of KO-539 in dosing cohorts which have&#xD;
      demonstrated early biological activity and have been determined to be safe as part of the&#xD;
      dose-escalation part.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 12, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Dose-expansion (part 1a) will employ a modified toxicity probability interval-2 (mTPI-2) adaptive design. Dose-validation/expansion (part 1b) will employ a Bayesian Logistic Regression Model.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1a: Maximal tolerated dose (MTD).</measure>
    <time_frame>Dose Limiting Toxicities (DLTs) will be evaluated during the first 28 days (1 cycle)</time_frame>
    <description>MTD is defined as the highest dose that is not expected to cause dose limiting toxicity (DLT) in more than 20% of patients.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1b: Number of patients that experience Adverse Events (AEs) and Serious Adverse Events (SAEs).</measure>
    <time_frame>During treatment and up to approximately 28 days after treatment discontinuation, or until immediately before the initiation of another anticancer therapy, whichever occurs first.</time_frame>
    <description>Assessed by NCI-CTCAE v5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1b: Minimal biologically effective dose</measure>
    <time_frame>Up to 6 months following end of treatment</time_frame>
    <description>Minimal biologically effective dose in dosing cohorts which have demonstrated biological activity and have been determined to be safe as a part of Part 1a</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1a: Number of patients that experience Adverse Events (AEs) and Serious Adverse Events (SAEs).</measure>
    <time_frame>During treatment and up to approximately 28 days after treatment discontinuation, or until immediately before the initiation of another anticancer therapy, whichever occurs first.</time_frame>
    <description>Assessed by NCI-CTCAE v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1a: Tmax</measure>
    <time_frame>Cycle 1 and Cycle 2. Each cycle is 28 days.</time_frame>
    <description>Time to observed maximum plasma concentration of KO-539</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1a: AUC(0-last)</measure>
    <time_frame>Cycle 1 and Cycle 2. Each cycle is 28 days.</time_frame>
    <description>Area under the plasma concentration-time curve from time 0 to time of last measurable concentration of KO-539</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1a: Cmax</measure>
    <time_frame>Cycle 1 and Cycle 2. Each cycle is 28 days.</time_frame>
    <description>Maximum plasma concentration of KO-539</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1a and 1b: Composite definition of complete remission (CR) and complete remission with partial hematologic recovery (CRh)</measure>
    <time_frame>Up to 6 months following discontinuation of treatment</time_frame>
    <description>To assess the CR (CR+CRh) rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1a and 1b: Complete response (CR) with and without minimal residual disease (MRD)</measure>
    <time_frame>Up to 6 months following discontinuation of treatment</time_frame>
    <description>To assess the CR rate with and without MRD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts 1a and 1b: Duration of remission (DOR)</measure>
    <time_frame>Up to 6 months following discontinuation of treatment</time_frame>
    <description>To assess the DOR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b: Transfusion independence (TI)</measure>
    <time_frame>Up to 6 months following discontinuation of treatment</time_frame>
    <description>To assess transfusion independence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b: Relapse-free survival (RFS)</measure>
    <time_frame>Up to 6 months following discontinuation of treatment</time_frame>
    <description>To assess relapse-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1b: Overall survival</measure>
    <time_frame>Up to 6 months following discontinuation of treatment</time_frame>
    <description>To assess overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Advanced Malignant Neoplasm</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Mixed Lineage Leukemia</condition>
  <condition>Mixed Lineage Acute Leukemia</condition>
  <condition>Acute Leukemia of Ambiguous Lineage</condition>
  <condition>Mixed Phenotype Acute Leukemia</condition>
  <arm_group>
    <arm_group_label>KO-539</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1a: Dose Escalation&#xD;
Part 1b: Dose-Validation/Expansion&#xD;
Cohort 1: KMT2A/NPM1 patients will receive a dose previously studied in Part 1a&#xD;
Cohort 2: KMT2A/NPM1 patients will receive a dose previously studied in Part 1a</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KO-539</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>KO-539</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Refractory or relapsed AML defined as the reappearance of &gt; 5% blasts in the bone&#xD;
             marrow and who have also failed or are ineligible for any approved standard of care&#xD;
             therapies, including HSCT.&#xD;
&#xD;
          2. ≥ 18 years of age.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.&#xD;
&#xD;
          4. Adequate liver and kidney function according to protocol requirements.&#xD;
&#xD;
          5. Peripheral white blood cell (WBC) counts ≤ 30,000/μL. Patients are allowed to receive&#xD;
             hydroxyurea to control and maintain WBC count prior to enrollment.&#xD;
&#xD;
          6. Both men and women (of childbearing potential) enrolled in this trial must use&#xD;
             adequate birth control measures during the course of the trial and for at least 90&#xD;
             days after their last dose of study treatment.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Donor lymphocyte infusion &lt; 30 days prior to study entry.&#xD;
&#xD;
          2. Clinically active central nervous system (CNS) leukemia.&#xD;
&#xD;
          3. Undergone HSCT and have not had adequate hematologic recovery (i.e. ANC &gt;1000 and&#xD;
             platelet count &gt; 100,000).&#xD;
&#xD;
          4. Receiving immunosuppressive therapy post HSCT at the time of screening (must be off&#xD;
             all immunosuppression therapy for at least 2 weeks). The use of topical steroids for&#xD;
             cutaneous GVHD is allowed and stable steroid doses less than or equal to 20 mg of&#xD;
             prednisone daily is permitted.&#xD;
&#xD;
          5. Grade &gt; 2 active graft-versus-host disease (GVHD), moderate or severe limited chronic&#xD;
             GVHD, or extensive chronic GVHD of any severity.&#xD;
&#xD;
          6. Received chemotherapy immunotherapy, or radiotherapy or any ancillary therapy that is&#xD;
             considered to be investigational (i.e., used for non-approved indications(s) and in&#xD;
             the context of a research investigation) &lt; 14 days prior to the first dose of KO-539&#xD;
             or within 5 drug half-lives (whichever is longer) prior to the first dose of study&#xD;
             drug.&#xD;
&#xD;
          7. Treatment with concomitant drugs that are strong inhibitors or inducers of cytochrome&#xD;
             P450-isozyme 3A4 (CYP3A4) with the exception of antibiotics, antifungals, and&#xD;
             antivirals that are used as standard of care or to prevent or treat infections and&#xD;
             other such drugs that are considered absolutely essential for the care of the patient.&#xD;
&#xD;
          8. Known detectable viral load for human immunodeficiency virus, hepatitis C, or&#xD;
             hepatitis B surface antigen indicative of active infection.&#xD;
&#xD;
          9. Active uncontrolled acute or chronic systemic fungal, bacterial, viral, or other&#xD;
             infection.&#xD;
&#xD;
         10. Significant cardiovascular disease including unstable angina pectoris, uncontrolled&#xD;
             hypertension or arrhythmia, history of cerebrovascular accident including transient&#xD;
             ischemic attack within the past 6 months, congestive heart failure (NYHA Class III or&#xD;
             IV) related to primary cardiac disease, ischemic or severe valvular heart disease, or&#xD;
             a myocardial infarction within 6 months prior to the first dose of study treatment.&#xD;
&#xD;
         11. QTcF &gt;480 ms.&#xD;
&#xD;
         12. Major surgery within 4 weeks prior to the first dose of study treatment.&#xD;
&#xD;
         13. Women who are pregnant or lactating. All female patients with reproductive potential&#xD;
             must have a negative pregnancy test prior to starting treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mary Pevear</last_name>
    <phone>781-346-9905</phone>
    <email>mpevear@kuraoncology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mollie Leoni, MD</last_name>
    <phone>617-302-9755</phone>
    <email>mleoni@kuraoncology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA Bowyer Oncology Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruck Habtemariam</last_name>
      <email>BHabtemariam@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>507-538-3365</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>jillian.weeks@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Comprehensive Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Weisenbach, RN</last_name>
      <phone>317-278-0597</phone>
      <email>Jweisenb@iupui.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Maryland Greenebaum Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Larissa Sanglard, MD</last_name>
      <phone>410-328-8370</phone>
      <email>larissa.sanglard@umm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Connolly</last_name>
      <email>CCONNOLLY1@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan Hospitals</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>800-865-1125</phone>
      <email>canceranswerline@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Center Clinical Trials Referral Office</last_name>
      <phone>855-776-0015</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Roswell Park Comprehensive Cancer Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>askroswell@roswellpark.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>hematologyresearch@duke.edu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felicia Kass</last_name>
      <email>kassfe2@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Recruitment and Eligibility Office</last_name>
      <phone>800-811-8480</phone>
      <email>cip@vumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harold C. Simmons Comprehensive Cancer Center - UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasmeen Akhtar, MBBS,MS,CCRP</last_name>
      <phone>214-648-5130</phone>
      <email>Yasmeen.Akhtar@UTSouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Abramowicz</last_name>
      <email>rrabramo@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaysey Orlowski</last_name>
      <email>korlowsk@fredhutch.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitat de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 25, 2019</study_first_submitted>
  <study_first_submitted_qc>August 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AML</keyword>
  <keyword>Hematological malignancy</keyword>
  <keyword>KMT2A</keyword>
  <keyword>NPM1</keyword>
  <keyword>Menin</keyword>
  <keyword>MLLr</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Acute Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Biphenotypic, Acute</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

